{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:32:37Z","timestamp":1783488757298,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>This study aimed to evaluate the impact of combined levothyroxine (LT4) and triiodothyronine (LT3) therapy on quality of life in patients with primary hypothyroidism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In a randomized, double-blind, parallel-group trial, 151 Iranian patients diagnosed with primary hypothyroidism between 2020 and 2021 were enrolled. One group received LT4 alone (<jats:italic>n<\/jats:italic>\u2009=\u200980), while the other received LT4 and LT3 (<jats:italic>n<\/jats:italic>\u2009=\u200971) for a minimum of six months. The primary outcome was quality of life assessed using the SF-36V1 questionnaire, and the secondary endpoints included clinical and laboratory measurements.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In the LT4\u2009+\u2009LT3 group, a significant reduction in TSH levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) was observed compared to baseline. While no significant differences emerged between the groups in terms of blood pressure, lipid profiles (except for low-density lipoprotein cholesterol), or body weight, there were notable improvements in physical functioning and bodily pain in the LT4\u2009+\u2009LT3 group compared to the LT4\u2009+\u2009placebo group. Compared with baseline, combination therapy significantly increased the physical component summary score after six months, but the difference was not significant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Combination therapy may benefit patients with primary hypothyroidism, particularly those experiencing body pain or physical function issues. However, the overall impact on quality of life remains inconclusive, as evidenced by the scores for the mental component. Further research is needed to determine the broader implications of this therapy. This study provides valuable insights into the potential advantages of combining LT4 and LT3 in the management of primary hypothyroidism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>The study was registered with the Iranian Registry of Clinical Trials (IRCT) and assigned the registration number IRCT20200410047012N1 on 2022\u201308-07.<\/jats:p>\n            <jats:p>Trial registration number: IRCT20200410047012N1.<\/jats:p>\n            <jats:p>Date of registration: 2020\u201306-12.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12902-025-01840-4","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T04:09:53Z","timestamp":1737864593000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early effects of LT3\u2009+\u2009LT4 combination therapy on quality of life in hypothyroid patients: a randomized, double-blind, parallel-group comparison trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Fatemeh","family":"Hajtalebi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariba","family":"Alaei-Shahmiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Golgiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najmeh","family":"Shahini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4880-6495","authenticated-orcid":false,"given":"Hamideh","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Assadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedarad","family":"Mosalamiaghili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1590\/2359-3997000000192","volume":"60","author":"J Kaminski","year":"2016","unstructured":"Kaminski J, et al. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Arch Endocrinol Metab. 2016;60:562\u201372.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"1840_CR2","first-page":"40","volume":"9","author":"P Colucci","year":"2013","unstructured":"Colucci P, et al. A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol. 2013;9(1):40\u20137.","journal-title":"Eur Endocrinol"},{"issue":"6","key":"1840_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1089\/thy.2017.0681","volume":"28","author":"SJ Peterson","year":"2018","unstructured":"Peterson SJ, et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018;28(6):707\u201321.","journal-title":"Thyroid"},{"issue":"6","key":"1840_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/eje.1.02025","volume":"153","author":"EM Wekking","year":"2005","unstructured":"Wekking EM, et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur J Endocrinol. 2005;153(6):747\u201353.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1840_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1046\/j.1365-2265.2002.01654.x","volume":"57","author":"P Saravanan","year":"2002","unstructured":"Saravanan P, et al. Psychological well-being in patients on \u2018adequate\u2019doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol. 2002;57(5):577\u201385.","journal-title":"Clin Endocrinol"},{"issue":"Suppl2","key":"1840_CR6","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.4103\/2230-8210.83333","volume":"15","author":"S Kalra","year":"2011","unstructured":"Kalra S, Khandelwal SK. Why are our hypothyroid patients unhappy? Is tissue hypothyroidism the answer? Indian J Endocrinol Metab. 2011;15(Suppl2):S95.","journal-title":"Indian J Endocrinol Metab"},{"issue":"7","key":"1840_CR7","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/jcm10071386","volume":"10","author":"F Borson-Chazot","year":"2021","unstructured":"Borson-Chazot F, et al. What is the quality of life in patients treated with levothyroxine for hypothyroidism and how are we measuring it? A critical, narrative review. J Clin Med. 2021;10(7):1386.","journal-title":"J Clin Med"},{"issue":"6","key":"1840_CR8","doi-asserted-by":"publisher","first-page":"e0156925","DOI":"10.1371\/journal.pone.0156925","volume":"11","author":"KH Winther","year":"2016","unstructured":"Winther KH, et al. Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy. PLoS ONE. 2016;11(6):e0156925.","journal-title":"PLoS ONE"},{"issue":"6","key":"1840_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1530\/EJE-09-0542","volume":"161","author":"B Nygaard","year":"2009","unstructured":"Nygaard B, et al. Effect of combination therapy with thyroxine (T4) and 3, 5, 3\u2032-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161(6):895\u2013902.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1840_CR10","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1210\/jc.2003-030139","volume":"88","author":"A Sawka","year":"2003","unstructured":"Sawka A, et al. Does a combination regimen of thyroxine (T4) and 3, 5, 3\u2032-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003;88(10):4551\u20135.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1840_CR11","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1210\/jc.2003-030249","volume":"88","author":"JP Walsh","year":"2003","unstructured":"Walsh JP, et al. Combined thyroxine\/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88(10):4543\u201350.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1840_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7326\/0003-4819-142-6-200503150-00007","volume":"142","author":"HF Escobar-Morreale","year":"2005","unstructured":"Escobar-Morreale HF, et al. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142(6):412\u201324.","journal-title":"Ann Intern Med"},{"key":"1840_CR13","unstructured":"National Institute for Health and Care Excellence. Thyroid disease: assessment and management. Management of hypothyroidism. NICE guideline NG145. 2019. cited 2022; Available from: https:\/\/www.nice.org.uk\/guidance\/ng145\/evidence\/e-management-of-hypothyroidism-pdf-6967421681."},{"issue":"2","key":"1840_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","volume":"1","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100\u20137.","journal-title":"J Pharmacol Pharmacother"},{"issue":"8","key":"1840_CR15","first-page":"1073","volume":"18","author":"MB Moghaddam","year":"2012","unstructured":"Moghaddam MB, et al. The Iranian version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073\u201380.","journal-title":"World Appl Sci J"},{"key":"1840_CR16","unstructured":"Ware JE, Keller SD, Kosinski M. SF-36: Physical and mental health summary scales: A user's manual. 1994: Health Assessment Lab."},{"issue":"3","key":"1840_CR17","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s11136-004-1014-5","volume":"14","author":"A Montazeri","year":"2005","unstructured":"Montazeri A, et al. The Short Form Health Survey (SF-36): translation and validation study of the Iranian version. Qual Life Res. 2005;14(3):875\u201382.","journal-title":"Qual Life Res"},{"issue":"11","key":"1840_CR18","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0895-4356(98)00081-X","volume":"51","author":"JE Ware Jr","year":"1998","unstructured":"Ware JE Jr, Gandek B. Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. J Clin Epidemiol. 1998;51(11):903\u201312.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"1840_CR19","first-page":"115","volume":"26","author":"L Jeyaseelan","year":"1989","unstructured":"Jeyaseelan L, Rao P. Methods of determining sample sizes in clinical trials. Indian Pediatr. 1989;26(2):115\u201321.","journal-title":"Indian Pediatr"},{"issue":"5","key":"1840_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000490383","volume":"7","author":"LF Michaelsson","year":"2018","unstructured":"Michaelsson LF, et al. Levothyroxine\/liothyronine combination therapy and quality of life: is it all about weight loss? Eur Thyroid J. 2018;7(5):243\u201350.","journal-title":"Eur Thyroid J"},{"issue":"6","key":"1840_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJM199902113400603","volume":"340","author":"R Bunevi\u010dius","year":"1999","unstructured":"Bunevi\u010dius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med. 1999;340(6):424\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1840_CR22","doi-asserted-by":"publisher","first-page":"e100870","DOI":"10.5812\/ijem.100870","volume":"18","author":"F Azizi","year":"2020","unstructured":"Azizi F, et al. LT4 and slow release T3 combination: optimum therapy for hypothyroidism? Int J Endocrinol Metab. 2020;18(2):e100870.","journal-title":"Int J Endocrinol Metab"},{"key":"1840_CR23","doi-asserted-by":"crossref","unstructured":"Premawardhana LD, et al. Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design. Front Endocrinol. 2023;14:1282608","DOI":"10.3389\/fendo.2023.1282608"},{"key":"1840_CR24","doi-asserted-by":"crossref","unstructured":"Madan R, Celi FS. Combination therapy for hypothyroidism: rationale, therapeutic goals, and design. Front Endocrinol. 2020;11:371.","DOI":"10.3389\/fendo.2020.00371"},{"issue":"3","key":"1840_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/07435800903156340","volume":"34","author":"M Valizadeh","year":"2009","unstructured":"Valizadeh M, et al. Efficacy of combined levothyroxine and liothyronine as compared with levothyroxine monotherapy in primary hypothyroidism: a randomized controlled trial. Endocr Res. 2009;34(3):80\u20139.","journal-title":"Endocr Res"},{"issue":"22","key":"1840_CR26","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1001\/jama.290.22.2952","volume":"290","author":"PW Clyde","year":"2003","unstructured":"Clyde PW, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA. 2003;290(22):2952\u20138.","journal-title":"JAMA"},{"issue":"7","key":"1840_CR27","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1210\/jc.2006-0448","volume":"91","author":"S Grozinsky-Glasberg","year":"2006","unstructured":"Grozinsky-Glasberg S, et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91(7):2592\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1840_CR28","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/MNM.0b013e32832c79e0","volume":"30","author":"M Chao","year":"2009","unstructured":"Chao M, et al. Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun. 2009;30(8):586\u201393.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1840_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/thy.2020.0720","volume":"31","author":"J Jonklaas","year":"2021","unstructured":"Jonklaas J, et al. Evidence-Based Use of Levothyroxine\/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid. 2021;31(2):156\u201382.","journal-title":"Thyroid"},{"issue":"2","key":"1840_CR30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1017\/S1461145700001826","volume":"3","author":"R Bunevicius","year":"2000","unstructured":"Bunevicius R, Prange AJ Jr. Mental improvement after replacement therapy with thyroxine plus triiodothyronine: relationship to cause of hypothyroidism. Int J Neuropsychopharmacol. 2000;3(2):167\u201374.","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01840-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T04:10:01Z","timestamp":1737864601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01840-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01840-4","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]},"assertion":[{"value":"27 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Gorgan University of Medical Sciences (IR.GOUMS.REC.1399.016), and written informed consent was obtained from all patients.Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}